Your browser is no longer supported. Please, upgrade your browser.
Settings
NBRV Nabriva Therapeutics plc daily Stock Chart
NBRV [NASD]
Nabriva Therapeutics plc
Index- P/E- EPS (ttm)-2.16 Insider Own0.10% Shs Outstand70.21M Perf Week-1.09%
Market Cap190.97M Forward P/E- EPS next Y-0.84 Insider Trans307.96% Shs Float69.24M Perf Month-14.20%
Income-114.80M PEG- EPS next Q-0.32 Inst Own53.20% Short Float0.59% Perf Quarter37.37%
Sales9.70M P/S19.69 EPS this Y9.30% Inst Trans-8.78% Short Ratio0.43 Perf Half Y-4.23%
Book/sh1.02 P/B2.67 EPS next Y30.60% ROA-111.90% Target Price9.50 Perf Year-47.49%
Cash/sh1.46 P/C1.87 EPS next 5Y- ROE-139.90% 52W Range1.12 - 6.05 Perf YTD86.30%
Dividend- P/FCF- EPS past 5Y-19.10% ROI-124.00% 52W High-55.04% Beta2.34
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low142.86% ATR0.21
Employees110 Current Ratio6.10 Sales Q/Q-27.30% Oper. Margin- RSI (14)51.57 Volatility6.10% 7.64%
OptionableYes Debt/Eq0.35 EPS Q/Q24.10% Profit Margin- Rel Volume0.67 Prev Close2.66
ShortableYes LT Debt/Eq0.35 EarningsMar 22 BMO Payout- Avg Volume949.91K Price2.72
Recom2.00 SMA20-1.79% SMA509.79% SMA20012.55% Volume641,091 Change2.26%
Sep-07-18Resumed Morgan Stanley Overweight
Mar-21-18Initiated BofA/Merrill Buy $10
Jan-17-18Initiated Morgan Stanley Overweight
Nov-01-17Reiterated H.C. Wainwright Buy $18 → $20
Aug-25-17Initiated SunTrust Buy $20
Feb-01-17Reiterated Wedbush Outperform $13
Oct-27-16Resumed Leerink Partners Outperform $14
Sep-08-16Initiated H.C. Wainwright Buy $16
Jan-27-16Initiated Gabelli & Co Buy $14
Nov-12-15Reiterated RBC Capital Mkts Outperform $21 → $22
Oct-13-15Initiated Wedbush Outperform
Oct-13-15Initiated RBC Capital Mkts Outperform $21
Oct-13-15Initiated Leerink Partners Outperform $19
Oct-12-15Initiated Needham Buy $15
Apr-12-19 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-11-19 07:00AM  Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO (fosfomycin for injection) to Treat Complicated Urinary Tract Infections (cUTIs) GlobeNewswire -7.41%
Apr-05-19 08:55AM  Do Options Traders Know Something About Nabriva Therapeutics (NBRV) Stock We Don't? Zacks
Apr-04-19 08:33AM  Nabriva Therapeutics (NBRV) in Focus: Stock Moves 7.5% Higher Zacks
Apr-02-19 07:00AM  Nabriva Therapeutics to Present at the Needham and Company 18th Annual Healthcare Conference GlobeNewswire +5.58%
Apr-01-19 07:00AM  Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-12-19 07:00AM  Nabriva Therapeutics Reports 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Feb-19-19 07:00AM  Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults GlobeNewswire
Jan-17-19 10:00AM  Antimicrobials Working Group Announces Updates to Leadership Team PR Newswire
Jan-15-19 08:58AM  Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7% Zacks
07:00AM  Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on January 23, 2019 GlobeNewswire
Jan-14-19 07:00AM  Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO GlobeNewswire +6.67%
Jan-04-19 07:00AM  Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous CONTEPO to Treat Complicated Urinary Tract Infections by FDA GlobeNewswire
Dec-21-18 12:01PM  Antibiotic developer Nabriva enters into $75M loan deal American City Business Journals -12.58%
07:00AM  Nabriva Therapeutics Announces Closing of up to a $75 million Term Loan GlobeNewswire
Dec-20-18 12:16PM  Nabriva files 2 NDAs seeking approval for experimental pneumonia treatment American City Business Journals
07:00AM  Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults GlobeNewswire
Nov-20-18 04:02PM  Nabriva Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-06-18 07:00AM  Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Nov-01-18 11:06AM  Nabriva files new drug application with FDA for urinary tract infection drug American City Business Journals +9.09%
07:00AM  Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO to Treat Complicated Urinary Tract Infections GlobeNewswire
Sep-28-18 07:00AM  Nabriva Therapeutics to Present Data at ID Week Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO (fosfomycin for injection) to Treat Complicated Urinary Tract Infections (cUTIs) GlobeNewswire
Sep-25-18 07:00AM  Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-10-18 08:48AM  Implied Volatility Surging for Nabriva Therapeutics plc (NBRV) Stock Options Zacks
Aug-09-18 07:00AM  Nabriva Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Aug-08-18 07:00AM  Nabriva Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire +5.04%
Jul-27-18 11:08AM  Antiobiotic developer plans $50M stock sale American City Business Journals -18.51%
08:44AM  Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter Benzinga
Jul-26-18 08:00PM  Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $50 Million GlobeNewswire -12.75%
Jul-25-18 04:01PM  Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares GlobeNewswire +6.97%
08:41AM  Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile Benzinga
08:30AM  Nabriva Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-24-18 04:01PM  Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics GlobeNewswire
Jul-19-18 07:26AM  Nabriva Therapeutics (NBRV) Enters Oversold Territory Zacks
Jul-05-18 07:25AM  Free Technical Reports on Novavax and Three Additional Biotech Equities ACCESSWIRE
Jun-06-18 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 PR Newswire
May-31-18 07:00AM  Nabriva Therapeutics to Present Lefamulin Data at ASM Microbe GlobeNewswire
May-29-18 07:00AM  Nabriva Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-23-18 02:29PM  Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx Zacks
May-22-18 08:00AM  Todays Research Reports on Stocks to Watch: Dova Pharmaceuticals and Nabriva Therapeutics ACCESSWIRE
May-21-18 12:33PM  King of Prussia biopharm firm posts positive study data for experimental pneumonia therapy American City Business Journals -16.57%
11:59AM  Why Nabriva Therapeutics Stock Is Falling Today Motley Fool
09:13AM  Nabriva's pneumonia drug succeeds late-stage study, shares surge Reuters
07:41AM  Nabriva Therapeutics unveils positive results in bacterial pneumonia drug trial MarketWatch
07:36AM  Nabriva's pneumonia drug succeeds in late-stage study Reuters
07:30AM  Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia GlobeNewswire
May-11-18 08:46AM  Is the Options Market Predicting a Spike in Nabriva Therapeutics (NBRV) Stock? Zacks
May-08-18 07:00AM  Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
May-07-18 12:02PM  Flavor Of The Month: OvaScience And More Simply Wall St.
Apr-25-18 07:00AM  Nabriva Therapeutics to Participate in Two Investor Conferences in May GlobeNewswire
Apr-20-18 10:17AM  Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-13-18 07:00AM  Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia GlobeNewswire
Mar-29-18 07:50AM  Blog Exposure - Nabriva Therapeutics Collaborated with Roivant to Commercialize Lefamulin in Greater China ACCESSWIRE
Mar-27-18 07:00AM  Nabriva Therapeutics and Roivant Sciences Enter into License Agreement to Develop and Commercialize Lefamulin in Greater China GlobeNewswire
Mar-21-18 07:00AM  Nabriva Therapeutics Appoints Jennifer Schranz, M.D., as Chief Medical Officer GlobeNewswire +5.38%
Mar-16-18 07:00AM  Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
Mar-14-18 07:00AM  Nabriva Therapeutics to Present at the Needham and Company 17th Annual Healthcare Conference GlobeNewswire
Feb-01-18 07:00AM  Nabriva Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Dec-13-17 04:05PM  Nabriva Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-04-17 07:00AM  Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults GlobeNewswire
Nov-30-17 07:00AM  Nabriva Therapeutics to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference GlobeNewswire
Nov-09-17 07:00AM  Nabriva Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
Oct-26-17 07:47AM  3 Companies Tackling the Antibiotic-Resistant Bacteria Crisis Motley Fool
Oct-25-17 07:00AM  Nabriva Therapeutics to Present at the Stifel 2017 Healthcare Conference GlobeNewswire
Sep-29-17 11:29AM  Weekly CFO Buys Highlights GuruFocus.com
Sep-28-17 04:58PM  Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017 GlobeNewswire
Sep-21-17 08:27AM  Nabriva Therapeutics latest good news soothes concerns about chief medical officers departure MarketWatch
Sep-20-17 05:22PM  Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire -10.12%
12:11PM  Why Nabriva Therapeutics Shares Are Falling Today Motley Fool
08:45AM  Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook Zacks
07:10AM  Corporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABP ACCESSWIRE
Sep-19-17 08:53PM  Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million GlobeNewswire
12:52PM  Here's Why Nabriva Therapeutics PLC Is Soaring Today Motley Fool
10:39AM  Nabriva's Lefamulin Positive in Pivotal Study, Stock Surges Zacks
09:58AM  Company News For Sep 19, 2017 Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Itus Corporation and Nabriva Therapeutics ACCESSWIRE
Sep-18-17 04:06PM  Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares GlobeNewswire +29.30%
01:42PM  Here's Why Nabriva Therapeutics (NBRV) Stock is Surging Today Zacks
12:43PM  Why Nabriva Therapeutics PLC Is Skyrocketing Motley Fool
10:44AM  A biotech stock doubled after it got positive results on a drug to tackle the leading cause of infectious death in the US Business Insider
10:06AM  US STOCKS-Wall St hits new record highs as financials, industrials gain Reuters
09:25AM  Stocks to Watch: Orbital ATK, Alphabet, Caterpillar, Equifax, Nabriva Therapeutics The Wall Street Journal
08:45AM  Why Nabriva Shares Are Doubling 24/7 Wall St.
07:49AM  UPDATE: Nabriva Therapeutics stock jumps 102% premarket on positive trial of pneumonia treatment MarketWatch
07:00AM  Nabriva Therapeutics Announces Positive Topline Results from Global, Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia GlobeNewswire
Aug-31-17 05:15PM  Nabriva Therapeutics Announces Resignation of Elyse Seltzer, M.D. GlobeNewswire
Aug-07-17 07:00AM  Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights GlobeNewswire +6.06%
Aug-02-17 07:00AM  Nabriva Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-11-17 07:00AM  Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer GlobeNewswire
Jun-26-17 08:00AM  Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board GlobeNewswire
07:00AM  Nabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding Common Shares of Nabriva Therapeutics AG and Outstanding American Depositary Shares of Nabriva Therapeutics AG GlobeNewswire
Jun-05-17 07:00AM  Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017 GlobeNewswire
Jun-02-17 07:00AM  Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin GlobeNewswire
May-23-17 07:00AM  Nabriva Commences Previously Announced Tender Offer Related to the Proposed Redomicile of its Holding Company from Austria to Ireland GlobeNewswire
May-10-17 04:05PM  Nabriva Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-17-17 07:00AM  Nabriva Announces the Proposed Redomicile of its Holding Company from Austria to Ireland, by means of an Exchange Offer GlobeNewswire
Apr-13-17 04:05PM  Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin GlobeNewswire
Apr-11-17 10:43AM  Nabriva Therapeutics AG :NBRV-US: Earnings Analysis: 2016 By the Numbers : April 11, 2017 Capital Cube +6.68%
07:00AM  Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia GlobeNewswire
Mar-31-17 08:00AM  Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors GlobeNewswire
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. Its lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections, as well as Pediatric oral formulation. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rowland Charles A JrDirectorDec 24Buy1.3153,00069,43053,000Dec 27 04:05 PM
Talbot George HarrisonDirectorJul 31Buy2.7514,50039,87547,640Aug 02 05:52 PM
BURGESS DANIEL DDirectorJul 31Buy2.7536,00099,00036,000Aug 02 05:51 PM
Gelone Steven P.Chief Scientific OfficerJun 23Buy3.8210,00038,20022,740Jun 26 09:09 AM
Broom Colin MDCEO & DirectorJun 22Buy3.725,00018,600102,151Jun 25 09:47 AM
Schranz JenniferChief Medical OfficerJun 22Buy3.735,50020,5155,500Jun 25 09:47 AM
Crotty RobertGeneral Counsel & SecretaryMay 23Buy4.4810,00044,80010,000May 23 12:29 PM
Lavino Francesco MariaChief Commercial OfficerMay 23Buy4.602,1609,9363,719May 29 01:48 PM
Sender GaryChief Financial OfficerMay 23Buy4.572,0009,1406,200May 23 08:38 PM
Webster Stephen WDirectorMay 23Buy4.598,00036,7208,000May 23 08:37 PM
Broom Colin MDCEO & DirectorMay 23Buy4.6010,00046,00097,151May 23 08:36 PM